Note this one-time change to our usual venue, date and time.
The odds of successfully moving a new drug treatment from the lab bench to commercial approval are 5000:1.
How do innovative biotech startup companies thrive in an age of austerity to turn the odds in their favor?
In this presentation, Mark Ahn, PhD, CEO of Galena Biopharma shares his views on the hype, hope, and opportunities ahead in the context of biotech industry innovation, performance and value creation.
Mark is CEO of Galena Biopharma (Nasdaq: GALE) and professor (adjunct) of biosciences at Creighton University. Prior to Galena, he was principal at Pukana Partners, life-science consultants, and associate professor of global management at Atkinson Graduate School of Management, Willamette University. He was also founder and CEO of Hana Biosciences, VP of hematology and corporate officer at Genentech, on staff at Amgen and Bristol-Myers Squibb, and in the US Army. He is a director of Access Pharmaceuticals, Mesynthes and Scribes STAT.
LAVA Healthcare is generously sponsored by
This event is co-produced with
About LAVA Healthcare
No one disputes that the U.S. healthcare system is a mess that has been deteriorating for decades. Many argue that increasing legislation and regulation will worsen the problem, others argue its the best solution.
LAVA Healthcare is an ongoing conversation about how we might fix the mess applying innovation across a wide range of dimensions including technology, business models, patient involvement, offshore outsourcing, and training programs.
The main goal is to foster innovation, while allowing our community to learn, be inspired, make valuable new business relationships and re-establish old ones. And perhaps even perhaps even influence public policy.
Who should participate? Everyone with an interest in the U.S. healthcare system such as technologists, life-sciences professionals and vendors, medical practitioners, healthcare providers, policy makers, and consultants of all types.
LAVA Healthcare operates with monthly meetings, a blog, and a LinkedIn group.
Each meeting features a presentations by one a healthcare innovator or investor who believes his/her ideas will have significant effects on the cost and quality of our healthcare system. Following the short presentation by the innovator, the audience criticizes, applauds, grinds, brainstorms, embellishes, refines, and pokes holes into the idea. There are no panelists or talking heads at the front of the room. The group leads the conversation: Is it a large problem? A small problem? A problem at all? Why is it a problem? What can be done about it? The conversation is directed and textured by the experience and knowledge of every member of the audience who poses questions, tells stories, and proposes answers.
Meetings are governed by five simple rules:
- Have fun, explore new and old ideas, make new friends and reconnect with old ones.
- Nothing is off topic as long as its about healthcare.
- No talking-head lectures: Everyone is a panelist.
- No preset course: The group leads the conversation.
- Self-promotions and sermons instantly lose the floor at moderator's sole discretion.